A proprietary Hub-and-Spoke architecture combining secure local AI execution with cloud-synced mobile intelligence. Designed for the institutional biotech investor.
A comprehensive local interface ensures that executing agent logic and proprietary datasets remain secure offline, while giving analysts a high-throughput visualization layer for the AI Council's signals.
The central command center. Runs locally on secure hardware. Orchestrates the agent swarm, ingests raw SEC/FDA data, and executes proprietary valuation algorithms completely offline.
The centralized screen where specialized AI agents present their synthesized findings. Features real-time tracking of catalyst events, institutional flow via Smart Money, and strategic options plays formulated by cross-agent consensus.
We don't rely on a single model. A swarm of specialized agents, each with a distinct persona and rigid specification, debate the investment thesis before human review.
THE DETECTIVE
Resolves complex corporate entity structures. Links obfuscated clinical trial sponsors to parent tickers using Wikidata and probabilistic matching.
THE STRATEGIST
Synthesizes inputs from all other agents. Calculates "Conviction Scores" and maps opportunities to specific proprietary playbooks (CSP vs Moonshot).
RISK ANALYST
Audits SEC 10-K filings for "Risk Factor" diffs. Flags silent changes in legal language that indicate undisclosed regulatory or IP threats.
VOLATILITY
Executes the "Cash-Secured Put" strategy. Scans option chains for high-IV opportunities backed by strong balance sheets and defined floors.
STRATEGY: CASH_SECURED_PUT
Targeting high implied volatility around binary events. We identify "Floor Prices" based on Net Cash and Book Value, selling premium only when the strike is mathematically defended.
STRATEGY: MOONSHOT
Identifying Mispriced Optionality. Screening for Small Cap (<$500M) companies with Orphan Drug Designation and near-term catalysts where the market ignores the TAM.
STRATEGY: FINANCIAL_HEALTH
"Cash is King". Survival analysis based on burn rates and cash equivalents. Ensuring companies have >18 months runway to withstand FDA delays without toxic dilution.
STRATEGY: DEEP_VALUE
Negative Enterprise Value. Identifying companies trading below their net liquidation value, effectively offering the clinical pipeline for free.